Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Income from Continuing Operations (2023 - 2025)

Compass Therapeutics' Income from Continuing Operations history spans 3 years, with the latest figure at 17990000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 8.56% year-over-year to 17990000.0; the TTM value through Dec 2025 reached 71506000.0, down 35.75%, while the annual FY2025 figure was 72839000.0, 28.63% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 17990000.0 at Compass Therapeutics, down from 15817000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 7837000.0 in Q1 2023 and bottomed at 21066000.0 in Q2 2025.
  • The 3-year median for Income from Continuing Operations is 13245500.0 (2023), against an average of 13889500.0.
  • The largest YoY upside for Income from Continuing Operations was 8.56% in 2025 against a maximum downside of 61.1% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 13415000.0 in 2023, then dropped by 23.53% to 16572000.0 in 2024, then dropped by 8.56% to 17990000.0 in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Income from Continuing Operations are 17990000.0 (Q4 2025), 15817000.0 (Q3 2025), and 21066000.0 (Q2 2025).